Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission

Affiliations

• ¹ Hematology and Bone Marrow Transplantation, Polytechnic University of Marche-Ospedali Riuniti, Ancona, Italy.
• ² National Registry GITMO & Data Managing, Ospedale San Martino, Genova, Italy.
• ³ Hematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S. Martino-IST, Genova, Italy.
• ⁴ Hematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University of Rome, Rome, Italy.
• ⁵ Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy.
• ⁶ Hematology 2 Unit, San Giovanni Battista Hospital and University, Turin, Italy.
• ⁷ Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy.
• ⁸ Department of Hematology, University of Pavia, Policlinico S Matteo-IRCCS, Pavia, Italy.
• ⁹ Hematology Department, University of Bari, Bari, Italy.
• ¹⁰ Department of Hematology and Bone Marrow Transplant Unit Ospedale Cervello, Palermo, Italy.
• ¹¹ Department of Hematology, S Bortolo Hospital, Vicenza, Italy.
• ¹² Institute of Haematology, Università Cattolica Sacro Cuore, Roma, Italy.
• ¹³ Haematology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
• ¹⁴ Hematology - BMT Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
• ¹⁵ Hematology and BMT Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.